第一单位：
Department of Medical Oncology, Sarah Cannon Research Institute, Nashville, Tennessee.
作者：
Erika,Hamilton [1]
;
Matthew D,Galsky [2]
;
Sebastian,Ochsenreither [3]
;
Gianluca,Del Conte [4]
;
Miguel,Martín [5]
;
Maria José,De Miguel [6]
;
Evan Y,Yu [7]
;
Anja,Williams [8]
;
Maria,Gion [9]
;
Antoinette R,Tan [10]
;
Laila,Agrawal [11]
;
Annemie,Rutten [12]
;
Jean-Pascal,Machiels [13]
;
Sara,Cresta [14]
;
Philip R,Debruyne [15]
;
Audrey,Hennequin [16]
;
Victor,Moreno [17]
;
Anna,Minchom [18]
;
Frances,Valdes-Albini [19]
;
Daniel,Petrylak [20]
;
Li,Li [21]
;
Zenta,Tsuchihashi [22]
;
Fumitaka,Suto [22]
;
Fu-Chih,Cheng [23]
;
Maha,Kandil [24]
;
Daniel,Barrios [25]
;
Sara,Hurvitz [26]
作者单位：
Department of Medical Oncology, Sarah Cannon Research Institute, Nashville, Tennessee.
[1]
Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.
[2]
Department of Hematology, Oncology and Cancer Immunology, Charité Comprehensive Cancer Center, Berlin, Germany.
[3]
Department of Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
[4]
Department of Medical Oncology, Hospital Gregorio Maranon, Madrid, Spain.
[5]
Early Phase Clinical Trial Unit, START Madrid CIOCC HM Sanchinarro, Madrid, Spain.
[6]
Department of Medicine, Fred Hutchinson Cancer Center and University of Washington, Seattle, Washington.
[7]
Clinical Research, Sarah Cannon Research Institute, London, United Kingdom.
[8]
Department of Medical Oncology, Hospital Ruber International, Madrid, Spain.;Ramón y Cajal University Hospital, Madrid, Spain.
[9]
Department of Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina.
[10]
Department of Medical Oncology, Norton Cancer Institute, Louisville, Kentucky.
[11]
Department of Medical Oncology, GZA Hospitals Campus Sint-Augustinus, Antwerp, Belgium.
[12]
Department of Medical Oncology, Institut Roi Albert II Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (UC Louvain, IREC), Brussels, Belgium.
[13]
Division of Medical Oncology, Department of Oncology and Hematology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
[14]
Kortrijk Cancer Centre, General Hospital AZ Groeninge, Kortrijk, Belgium.;Medical Technology Research Centre (MTRC), School of Life Sciences, Anglia Ruskin University, Cambridge, United Kingdom.;School of Nursing and Midwifery, University of Plymouth, Plymouth, United Kingdom.
[15]
Department of Medical Oncology, Centre Georges Francois Leclerc, Dijon, France.
[16]
Early Phase Trials Unit, START Madrid-FJD, Fundacion Jimenez Diaz, Madrid, Spain.
[17]
Drug Development Unit, Royal Marsden Hospital, Sutton, United Kingdom.
[18]
Division of Medical Oncology, Department of Medicine, University of Miami Hospital & Clinics, Sylvester Comprehensive Cancer Center, Miami, Florida.;Department of Medical Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida.
[19]
Division of Genitourinary Oncology, Yale University, New Haven, Connecticut.
[20]
Quantitative Clinical Pharmacology, Daiichi Sankyo, Inc., Basking Ridge, New Jersey.
[21]
Department of Translational Science, Daiichi Sankyo, Inc., Basking Ridge, New Jersey.
[22]
Biostatistics and Data Management, Daiichi Sankyo, Inc., Basking Ridge, New Jersey.
[23]
CSPV, Daiichi Sankyo, Inc., Basking Ridge, New Jersey.
[24]
Department of Global Oncology R&D, Daiichi Sankyo, Inc., Basking Ridge, New Jersey.
[25]
Department of Medicine, Fred Hutchinson Cancer Center and University of Washington, Seattle, Washington.;Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California.
[26]
DOI
10.1158/1078-0432.CCR-24-1513
PMID
39405343
发布时间
2025-01-04
换一批
换一批
